Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Income from Continuing Operations (2023 - 2024)

Sagimet Biosciences has reported Income from Continuing Operations over the past 2 years, most recently at 16201000.0 for Q4 2024.

  • Quarterly results put Income from Continuing Operations at 16201000.0 for Q4 2024, down 98.74% from a year ago — trailing twelve months through Dec 2024 was 45567000.0 (down 63.45% YoY), and the annual figure for FY2025 was 51038000.0, down 12.01%.
  • Income from Continuing Operations for Q4 2024 was 16201000.0 at Sagimet Biosciences, down from 14619000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for SGMT hit a ceiling of 6357000.0 in Q3 2023 and a floor of 16201000.0 in Q4 2024.